Cargando…
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
The RAS family of proto-oncogenes are among the most commonly mutated genes in human cancers and predict poor clinical outcome. Several mechanisms underlying oncogenic RAS transformation are well documented, including constitutive signaling through the RAF-MEK-ERK proproliferative pathway as well as...
Autores principales: | Lim, Jonathan K. M., Delaidelli, Alberto, Minaker, Sean W., Zhang, Hai-Feng, Colovic, Milena, Yang, Hua, Negri, Gian Luca, von Karstedt, Silvia, Lockwood, William W., Schaffer, Paul, Leprivier, Gabriel, Sorensen, Poul H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511045/ https://www.ncbi.nlm.nih.gov/pubmed/31000598 http://dx.doi.org/10.1073/pnas.1821323116 |
Ejemplares similares
-
Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
por: Arensman, Michael D., et al.
Publicado: (2019) -
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
por: Jyotsana, Nidhi, et al.
Publicado: (2022) -
The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility
por: Shin, Chun-Shik, et al.
Publicado: (2017) -
Implication of the glutamate–cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis
por: Fournier, M., et al.
Publicado: (2017) -
Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury
por: Meyer, Anne R., et al.
Publicado: (2019)